Dexcom G7 CGM Earns Health Canada Approval

Dexcom has received Health Canada approval for its next-gen Dexcom G7 continuous glucose monitoring (CGM) system for people with all types of diabetes aged two and older.
 
According to the company, using Dexcom G7 has been shown to reduce hospitalizations and emergency room visits due to hypoglycemia by up to 42%.
 
“For more than two decades, Dexcom has had a singular focus on sensor technology, consistently working to evolve our CGM systems by listening to the needs of people with diabetes and their caregivers, making diabetes management easier for people around the world,” André Côté, VP and GM, Dexcom Canada told the press. “With our latest advancements in sensor technology and software integrations, we’re entering a new era of diabetes care with continuous glucose monitoring at the centre. Dexcom G7 builds on the innovation that our previous CGM systems have brought to the lives of Canadians. With greater accuracy, a simplified user experience, proven results and extensive digital connectivity, our next-generation Dexcom G7 will support greater quality of life and improved outcomes for people with diabetes, and we couldn’t be more excited to bring it to Canada by the end of 2023.”
 
Dexcom G7’s low-profile, all-in-one sensor and transmitter, according to Dexcom, warms up two times faster than other CGMs on the market. Users can see real-time glucose readings sent automatically to compatible smart devices or receivers without the need to scan or prick their finger routinely.
 
It can warn of high or low glucose levels with a predictive urgent low alert and help users spend more time in range.
 
“Real-time continuous glucose monitoring (rtCGM) has become the standard of care for many people living with diabetes, with clinical evidence supporting its effectiveness for reducing A1C, increasing time spent in the target glucose range, reducing the number of low glucose events and reducing the time spent with dangerous low glucose,” said Alice Cheng, Endocrinologist at Trillium Health Partners, Credit Valley Hospital and St. Michael’s Hospital (Unity Health Toronto). “With approval of Dexcom G7, the newest glucose sensor to come to Canada, patients will have a new, simple to start and easy to use tool in their diabetes management toolbox to effectively manage their diabetes and make important health decisions backed by health data and proven results.”
 
Dexcom G7 earned CE mark approval in March 2022, and FDA approval in December 2022.